Paul Tudor Jones Intellia Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 14,400 shares of NTLA stock, worth $175,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,400

Previous 24,803 41.94%

Holding current value

$175,248

Previous $509,000 67.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$19.72 - $27.36 $729,245 - $1.01 Million	-36,980 Reduced 59.85%	24,803 $509,000
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $286,446 - $389,463	14,308 Added 30.14%	61,783 $1.38 Million
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $1.13 Million - $1.56 Million	47,475 New	47,475 $1.31 Million
Q3 2023 Nov 15, 2023	BUY	$31.62 - $45.78 $241,513 - $349,667	7,638 New	7,638 $241,000
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $458,862 - $866,187	13,817 Added 44.45%	44,902 $1.57 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $1.68 Million - $2.23 Million	31,085 New	31,085 $1.74 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $741,817 - $1.47 Million	-19,273 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $1.12 Million - $2.29 Million	19,273 New	19,273 $1.4 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $1.22 Million - $1.68 Million	-12,109 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $616,049 - $822,734	4,654 Added 62.43%	12,109 $1.62 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $453,860 - $1.21 Million	7,455 New	7,455 $1.21 Million

Others Institutions Holding NTLA

# of Institutions

336

Shares Held

96.1M

Call Options Held

1.06M

Put Options Held

863K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $925M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account